Technology ID
TAB-4836
Candidacy of PfCg4 as a Transmission-Blocking Malaria Vaccine: A Comprehensive Assessment of its Prospective Role
E-Numbers
E-010-2014-0
Lead Inventor
Narum, David
Lead IC
NIAID
Co-Inventors
Aebig, Joan
Macdonald, Nicholas
ICs
NIAID
Applications
Vaccines
Therapeutics
Therapeutic Areas
Rare/Neglected Diseases
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Research Products
Research Equipment
Antibodies
In this study, the research explores the potential of PfCg4, a novel heat shock protein, as a candidate for a transmission-blocking malaria vaccine. By producing recombinant PfCg4 and conducting experiments demonstrating its susceptibility to antibody blockade in the mosquito midgut, the study presents evidence for its vaccine candidacy. This discovery holds promise for enhancing current efforts to combat malaria transmission and potentially offers cross-species transmission-blocking activity, given its similarity to the P. vivax Cg4 protein. This research marks a significant step towards the development of an effective tool in the fight against malaria.
Commercial Applications
The potential applications of PfCg4 in the field of malaria control are significant. If successfully developed into a vaccine, PfCg4 could play a pivotal role in blocking the transmission of the malaria parasite from mosquitoes to humans. This could aid in reducing the spread of malaria in endemic regions and contribute to the global efforts for malaria elimination and eradication. Furthermore, its cross-species transmission-blocking potential may extend its applicability to other malaria-causing species, enhancing its impact on a broader scale. PfCg4 holds promise as a vital tool in the fight against this deadly disease.
Competitive Advantages
PfCg4's competitive advantages stem from its unique properties as a transmission-blocking malaria vaccine candidate. It is the first heat shock protein shown to be susceptible to antibody blockade in the mosquito midgut, with scalable production capabilities for human clinical trials. Its conservation with P. vivax Cg4 also hints at cross-species transmission-blocking potential, making PfCg4 a promising tool for malaria control.
Licensing Contact: